FBXO21 expression based on
|
CHOL : Cholangiocarcinoma *
Please note that low number(<10) of normal samples considered.
Comparison | Statistical significance |
Normal-vs-Primary | 3.98480004548674E-09 |
|
CHOL : Cholangiocarcinoma *
Please note that low number(<10) of normal samples considered.
Show statistics |
Hide statistics |
Comparison |
Statistical significance |
Normal-vs-Stage1 |
2.07439999999615E-05 |
Normal-vs-Stage2 |
5.939500E-03 |
Normal-vs-Stage3 |
N/A |
Normal-vs-Stage4 |
1.804030E-02 |
Stage1-vs-Stage2 |
9.165000E-01 |
Stage1-vs-Stage3 |
N/A |
Stage1-vs-Stage4 |
7.641800E-01 |
Stage2-vs-Stage3 |
N/A |
Stage2-vs-Stage4 |
8.671800E-01 |
Stage3-vs-Stage4 |
N/A |
|
|
CHOL : Cholangiocarcinoma *
Please note that low number(<10) of normal samples considered.
Show statistics |
Hide statistics |
Comparison |
Statistical significance |
Normal-vs-Caucasian |
2.25500000006207E-07 |
Normal-vs-AfricanAmerican |
1.658640E-01 |
Normal-vs-Asian |
1.954290E-02 |
Caucasian-vs-AfricanAmerican |
2.367000E-01 |
Caucasian-vs-Asian |
9.280800E-01 |
AfricanAmerican-vs-Asian |
1.705620E-01 |
|
|
CHOL : Cholangiocarcinoma *
Please note that low number(<10) of normal samples considered.
Show statistics |
Hide statistics |
Comparison |
Statistical significance |
Normal-vs-Male |
2.028300E-04 |
Normal-vs-Female |
1.91321999999383E-05 |
Male-vs-Female |
6.009800E-01 |
|
|
CHOL : Cholangiocarcinoma *
Please note that low number(<10) of normal samples considered.
Note
Patient BMI information is not available for 1 sample.
Descriptions |
Normal weight |
BMI greater than equal to 18.5 and BMI less than 25 |
Extereme weight |
BMI greater than equal to 25 and BMI less than 30 |
Obese |
BMI greater than equal to 30 and BMI less than 40 |
Extreme Obese |
BMI greater than 40 |
Show statistics |
Hide statistics |
Comparison |
Statistical significance |
Normal-vs-Normal_Weight |
4.701200E-03 |
Normal-vs-Extreme_Weight |
9.6858000000033E-05 |
Normal-vs-Obese |
1.817030E-03 |
Normal-vs-Extreme_Obese |
N/A |
Normal_Weight-vs-Extreme_Weight |
2.605800E-01 |
Normal_Weight-vs-Obese |
1.466410E-02 |
Normal_Weight-vs-Extreme_Obese |
N/A |
Extreme_Weight-vs-Obese |
1.731960E-02 |
Extreme_Weight-vs-Extreme_Obese |
N/A |
Obese-vs-Extreme_Obese |
N/A |
|
|
CHOL : Cholangiocarcinoma *
Please note that low number(<10) of normal samples considered.
Show statistics |
Hide statistics |
Comparison |
Statistical significance |
Normal-vs-Age(21-40Yrs) |
1.10749964754575E-10 |
Normal-vs-Age(41-60Yrs) |
9.358000E-04 |
Normal-vs-Age(61-80Yrs) |
1.64043999999475E-05 |
Normal-vs-Age(81-100Yrs) |
3.828400E-01 |
Age(21-40Yrs)-vs-Age(41-60Yrs) |
2.536300E-03 |
Age(21-40Yrs)-vs-Age(61-80Yrs) |
2.075400E-03 |
Age(21-40Yrs)-vs-Age(81-100Yrs) |
2.808200E-02 |
Age(41-60Yrs)-vs-Age(61-80Yrs) |
8.444400E-01 |
Age(41-60Yrs)-vs-Age(81-100Yrs) |
5.197200E-01 |
Age(61-80Yrs)-vs-Age(81-100Yrs) |
4.683600E-01 |
|
|
CHOL : Cholangiocarcinoma
Subtype descriptions |
Grade 1 | Well differentiated (low grade) |
Grade 2 | Moderately differentiated (intermediate grade) |
Grade 3 | Poorly differentiated (high grade) |
Grade 4 | Undifferentiated (high grade) |
Show statistics |
Hide statistics |
Comparison |
Statistical significance |
Normal-vs-Grade 1 |
N/A |
Normal-vs-Grade 2 |
4.442800E-01 |
Normal-vs-Grade 3 |
3.531000E-01 |
Normal-vs-Grade 4 |
1.000000E+00 |
Grade 1-vs-Grade 2 |
N/A |
Grade 1-vs-Grade 3 |
N/A |
Grade 1-vs-Grade 4 |
N/A |
Grade 2-vs-Grade 3 |
3.472800E-01 |
Grade 2-vs-Grade 4 |
4.442800E-01 |
Grade 3-vs-Grade 4 |
3.531000E-01 |
|
|
CHOL : Cholangiocarcinoma *
Please note that low number(<10) of normal samples considered.
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 5 samples.
pathologic_N descriptions |
N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
Comparison |
Statistical significance |
Normal-vs-N0 |
9.94360000006189E-07 |
Normal-vs-N1 |
2.380400E-02 |
N0-vs-N1 |
2.950800E-01 |
|
|